704 - Ovarian Cancer: Drugs (Answered)

Mrs Sharon Hodgson
To ask the Secretary of State for Health, what assessment his Department has made of the effects of the decision by the Cancer Drugs Fund not to fund olaparib for patients with BRCA-mutated ovarian cancer.

George Freeman

The operation of the Cancer Drugs Fund (CDF), including the evaluation of new drugs for potential inclusion in the Fund, is a matter for NHS England’s CDF panel to consider alongside applications for new drugs to be added to the Fund on the basis of the clinical benefit a drug provides in relation to its cost. NHS England’s decision summary for olaparib as a maintenance treatment for relapsed BRCA-mutated high grade ovarian cancer can be found at:

www.england.nhs.uk/wp-content/uploads/2015/05/cdf-decision-olaparib.pdf

The National Institute for Health and Care Excellence is currently consulting on draft guidance on olaparib for use in certain ovarian, fallopian tube, and peritoneal cancers. This consultation is available at:

www.nice.org.uk/guidance/indevelopment/GID-TAG481/consultation